Athiththan Yogeswaran, Henning Gall, Meike Fünderich, Martin R Wilkins, Luke Howard, David G Kiely, Allan Lawrie, Paul M Hassoun, Yuriy Sirenklo, Olena Torbas, Andrew J Sweatt, Roham T Zamanian, Paul G Williams, Marlize Frauendorf, Alexandra Arvanitaki, George Giannakoulas, Khaled Saleh, Hani Sabbour, Hector R Cajigas, Robert Frantz, Imad Al Ghouleh, Stephen Y Chan, Evan Brittain, Jeffrey S Annis, Antonella Pepe, Stefano Ghio, Stylianos Orfanos, Anastasia Anthi, Raphael W Majeed, Jochen Wilhelm, Hossein Ardeschir Ghofrani, Manuel J Richter, Friedrich Grimminger, Sandeep Sahay, Khodr Tello, Werner Seeger
BACKGROUND: Pulmonary hypertension (PH) is a heterogeneous disease with poor prognosis. Accurate risk stratification is essential for guiding treatment decisions in pulmonary arterial hypertension (PAH). While various risk models were developed for PAH, their comparative prognostic potential requires further exploration. Additionally, the applicability of risk scores in PH groups beyond group 1 remains to be investigated. RESEARCH QUESTION: Are risk scores originally developed for PAH predictive in PH group 1-4? STUDY DESIGN AND METHODS: We conducted a comprehensive analysis of outcomes among incident PH patients enrolled in the multicenter worldwide PVRI-GoDeep meta-registry...
March 18, 2024: Chest